Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions

被引:15
|
作者
Haller, F. [1 ]
Loebke, C. [2 ]
Ruschhaupt, M. [2 ,3 ]
Schulten, H-J [1 ]
Schwager, S. [1 ]
Gunawan, B. [1 ]
Armbrust, T. [4 ]
Langer, C. [5 ]
Ramadori, G. [4 ]
Sueltmann, H. [2 ]
Poustka, A. [2 ]
Korf, U. [2 ]
Fuezesi, L. [1 ]
机构
[1] Univ Gottingen, Dept Pathol, D-37099 Gottingen, Germany
[2] German Canc Res Ctr, Div Mol Genome Anal, D-6900 Heidelberg, Germany
[3] Univ Munich, Sch Med, Dept Med Informat Biometr & Epidemiol, Munich, Germany
[4] Univ Gottingen, Dept Gastroenterol & Endocrinol, D-37099 Gottingen, Germany
[5] Univ Gottingen, Dept Gen & Visceral Surg, D-37099 Gottingen, Germany
来源
JOURNAL OF PATHOLOGY | 2008年 / 216卷 / 02期
关键词
GIST; KIT; cyclin D; MAP kinase; signalling; RB phosphorylation;
D O I
10.1002/path.2402
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumours (GISTs) with deletions in KIT exon 11 are characterized by higher proliferation rates and shorter disease-free survival times, compared to GISTs with KIT exon 11 point mutations. Up-regulation of cyclin D is a crucial event for entry into the G1 phase of the cell cycle, and links mitogenic signalling to cell proliferation. Signalling from activated KIT to cyclin D is directed through the RAS/RAF/ERK, PI3K/AKT/mTOR/EIF4E, and JAK/STATs cascades. ERK and STATs initiate mRNA transcription of cyclin D, whereas EIF4E activation leads to increased translation efficiency and reduced degradation of cyclin D protein. The aim of the current study was to analyse the mRNA and protein expression as well as protein phosphorylation of central hubs of these signalling cascades in primary GISTs, to evaluate whether tumours with KIT exon 11 deletions and point mutations differently utilize these pathways. GISTs with KIT exon 11 deletions had significantly higher mitotic counts, higher proliferation rates, and shorter disease-free survival times. In line with this, they had significantly higher expression of cyclin D on the mRNA and protein level. Furthermore, there was a significantly higher amount of phosphorylated ERK1/2, and a higher protein amount of STAT3, mTOR, and EIF4F. PI3K and phosphorylated AKT were also up-regulated, but this was not significant. Ultimately, GISTs with KIT exon 11 deletions had significantly higher phosphorylation of the central negative cell-cycle regulator RB. Phosphorylation of RB is accomplished by activated cyclin D/CDK4/6 complex, and marks a central event in the release of the cell cycle. Altogether, these observations suggest increased KIT signalling with up-regulation of cyclin D as the basis for the unfavourable clinical course in GISTs with KIT exon 11 deletions. Copyright (C) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:225 / 235
页数:11
相关论文
共 3 条
  • [1] HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs)
    Wei, Yu-Ching
    Chou, Fong-Fu
    Li, Chien-Feng
    Li, Wei-Ming
    Chen, Yen-Yang
    Lan, Jui
    Li, Shau-Hsuan
    Fang, Fu-Min
    Hu, Tsung-Hui
    Yu, Shih-Chen
    Eng, Hock-Liew
    Uen, Yih-Huei
    Tian, Yu-Fang
    Wang, Jui-Chu
    Huang, Hsuan-Ying
    HISTOPATHOLOGY, 2013, 63 (04) : 445 - 454
  • [2] Epithelioid/mixed phenotype in gastrointestinal stromal tumors with KIT mutation from the stomach is associated with accelerated passage of late phases of the cell cycle and shorter disease-free survival
    Haller, Florian
    Cortis, Judith
    Helfrich, Joel
    Cameron, Silke
    Schueler, Philipp
    Schwager, Stefanie
    Gunawan, Bastian
    Fuezesi, Laszlo
    Agaimy, Abbas
    MODERN PATHOLOGY, 2011, 24 (02) : 248 - 255
  • [3] Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
    Incorvaia, Lorena
    Badalamenti, Giuseppe
    Fanale, Daniele
    Vincenzi, Bruno
    Luca, Ida De
    Algeri, Laura
    Barraco, Nadia
    Brando, Chiara
    Bonasera, Annalisa
    Bono, Marco
    Castiglia, Marta
    Cancelliere, Daniela
    Cani, Massimiliano
    Rita Corsini, Lidia
    Fiorino, Alessia
    Galvano, Antonio
    Pedone, Erika
    Perez, Alessandro
    Pivetti, Alessia
    Graceffa, Giuseppa
    Pantuso, Gianni
    Cabibi, Daniela
    Russo, Antonio
    Bazan, Viviana
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13